China News Service, December 21. Zheng Zhongwei, the leader of the vaccine research and development team of the State Council’s Joint Prevention and Control Mechanism Research Team and Director of the National Health and Health Commission’s Medical Science and Technology Development Research Center, said on the 21st that China’s new crown vaccine is developing phase I and II In Phase III and Phase III clinical trials, as well as the emergency vaccination of nearly one million people in China under the premise of voluntary and informed consent in accordance with laws and regulations, some of the vaccinators had mild adverse reactions but no serious adverse reactions, which fully demonstrated China's new crown vaccine is very safe.
The State Council’s Joint Prevention and Control Mechanism held a press conference on the prevention and control of the winter and spring epidemics and the vaccination of key populations on the 21st. Zheng Zhongwei made the above statement at the press conference on whether the new crown vaccination is safe and effective.
Zheng Zhongwei said that the safety and effectiveness of vaccines are of great concern to everyone. The safety and effectiveness of vaccines are also the two most critical quality indicators for evaluating vaccines.
"Generally speaking, the safety of a vaccine refers to whether our recipients will have adverse reactions after vaccination, and whether serious adverse reactions will occur. If there are no serious adverse reactions, we generally think that the vaccine is safe".
Zheng Zhongwei introduced that in the process of vaccine development, animal trials, phase I clinical trials, phase II clinical trials, and phase III clinical trials must be carried out successively.
In the course of these experiments, it is necessary to evaluate whether the vaccine will produce adverse reactions in animals and humans, and the extent of the adverse reactions, and finally conclude whether the vaccine is safe.
Zheng Zhongwei stated that at the press conference on the joint prevention and control mechanism on December 18, it was introduced that the phase I, phase II, and phase III clinical trials of the new crown vaccine in my country, and that the country has already implemented voluntary and informed consent in accordance with laws and regulations. The emergency vaccination of nearly one million people has fully demonstrated that my country's new crown vaccine is very safe, with some minor adverse reactions, but no serious adverse reactions.
What is the current effect of my country's new crown vaccine? Zheng Zhongwei said that this has yet to be analyzed by the vaccine's phase III clinical trial endpoints or mid-term unblinding results before we can get specific data on the effectiveness of this vaccine. "But in Phase I and Phase II, we actually have some reference indicators for effectiveness. For example, we will compare the immunogenicity indicators of the vaccine group and the control group, such as neutralizing antibodies. Through this comparison, we find that in Phase I , Phase II clinical trial data shows that China’s new crown vaccine has good safety and effectiveness. At the same time, during our emergency use, more than 60,000 vaccinators have been to high-risk areas abroad. There has also not been a report of a serious infection case, which also proves from another angle that our vaccine has a certain protective effect."